Ex-’Bama RB says he will play for Rebels
Tenpenny once was one of nation’s top prep rushers
Altee Tenpenny was one of the nation’s top running backs when he signed with Alabama in 2013. Now he will play football at UNLV. Tenpenny made the announcement on his Instagram account, which is private but was reported by al.com, a website for several Alabama newspapers.
Tenpenny (6 feet, 218 pounds), will have to sit out next season under NCAA transfer rules, and then he will have two seasons of eligibility. Rebels coach Tony Sanchez is not allowed to comment on Tenpenny until he enrolls.
Tenpenny was widely regarded as the best high school senior in Arkansas when he signed two years ago out of North Little Rock High School. Tenpenny was ranked the nation’s No. 3 running back by MaxPrep’s Tom Lemming, No. 5 by 247Sports.com, No. 8 by Rivals.com and No. 14 by Scout.com.
The consensus four-star recruit played in the U.S. Army All-American
Didn’t see much playing time with Tide
oversaw the prefight drug testing for both fighters, was aware of Pacquiao’s use of those drugs.
Pacquiao was looking to receive a shot of Toradol, an anti-inflammatory drug, before he entered the ring Saturday. But the commission refused to allow the shot to be administered because of what was on the questionnaire.
Pacquiao fought without the use of the medicine and he claimed to have reinjured the shoulder during the third round. Yet, he hurt Mayweather in the fourth round and had another excellent round in the sixth. All three judges gave Pacquiao the fourth and sixth rounds in a fight he eventually lost by scores of 118110, 116-112 and 116-112.
Meanwhile, Pacquiao’s team issued a statement Monday claiming the NAC was aware of his injured shoulder five days before he and Mayweather fought at the sold-out Grand Garden.
The statement read, in part: “On his pre-fight medical form filled out earlier in the week, Manny’s advisers listed the medication that Manny used in training and the medications that might be used on fight night. A few hours before he was expected to step into the ring when Manny’s doctors began the process, the Nevada Commission stopped the treatment because it said it was unaware of Manny’s shoulder injury.
“This was disappointing to Team Pacquiao since they had disclosed the injury and treatment to USADA, USADA approved the treatments and Manny had listed the medication on his pre-fight medical form.”
NAC chairman Francisco Aguilar maintained his stance from late Saturday that the commission was not aware of Pacquiao’s injury and that his prefight medical questionnaire clearly stated the fighter did not have an injury. He also said the commission, not USADA, has control over the fight along with the protocols connected to the fight.
“Just because they disclosed it to USADA doesn’t mean they disclosed it to the commission,” Aguilar said Monday. “USADA doesn’t have jurisdiction over the event.”
Aguilar said he has asked the state attorney general’s office to look into the matter. Pacquiao could be guilty of misleading the commission or committing perjury with his responses to the questionnaire. When a fighter signs off on a form for the commission, there’s a line that says: “I hearby swear, under penalty of perjury, that the above information is true and correct to the best of my knowledge.”
Pacquiao signed the form. So did his adviser, Michael Koncz.
The commission may demand that Pacquiao appear in front of it at its June meeting and explain his side. The next commission meeting is scheduled for May 15 but Aguilar said he won’t have received a response from the AG’s office in time to put it on the May agenda.
“The attorney general will look at the disclosure, gather all the facts, make an analysis and come back with a recommendation to the commission as to how to proceed,” Aguilar said. “If we decide to have a hearing, Mr. Pacquiao and his team will have every opportunity to explain themselves to the commission and, if any discipline is needed, it would be determined at such a hearing.” Contact reporter Steve Carp at scarp@reviewjournal.com or 702-387-2913. Follow him on TRwitter: @stevecarprj.